- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02166593
Clinical Trial to Evaluate the Efficacy and Safety of Pravafenix Cap to Verify the Superiority Than Atorvastatin
September 27, 2018 updated by: Yooyoung Pharmaceutical Co., Ltd.
A Study to Evaluate the Efficacy and Safety of Pravastatin/Fenofibrate Complex in Patients With Combined Dyslipidemia With Adequately Controlled LDL-C But Inadequately Controlled Triglyceride Level by Atorvastatin Monotherapy
- Target disease : Patients with combined dyslipidemia with adequately controlled LDL-C but inadequately controlled triglyceride level by atorvastatin monotherapy
- Study objective : The objective of this study is to demonstrate that Pravafenix Cap. is clinically superior to atorvastatin by evaluating a percent change in Non-HDL-C in each group after 8 weeks treatment with atorvastatin or Pravafenix Cap. (pravastatin sodium/fenofibrate) in patients with adequately controlled LDL-C but inadequately controlled triglyceride level by atorvastatin monotherapy in a multicenter, randomized, double blind setting.
- Phase and design : A multicenter, double blind, randomized, active controlled, parallel-design, Phase 3 study
- Duration of study : 12 months from the IRB approval date
- Duration of administration : 4-week single blind run-in period plus 8-week double blind treatment period
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is to Evaluate the Efficacy and Safety of Pravastatin/Fenofibrate Complex in Patients With Combined Dyslipidemia With Adequately Controlled LDL-C But Inadequately Controlled Triglyceride Level by Atorvastatin Monotherapy.
After administrating the atorvastatin or Pravafenix Cap.
(pravastatin sodium/fenofibrate) for 8 weeks, evaluate the variation of the Non-HDL-C for each arm.
Ultimatly verificaite the Pravafenix Cap.
(pravastatin sodium/fenofibrate) have better effects than atorvastatin.
Study Type
Interventional
Enrollment (Actual)
302
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Screening visit (Pre-Study Visit :D-28)
- Men and women at the age ≥ 20 and < 80
Patients at a high risk of coronary heart disease according to the NCEP ATPIII guidelines
- Patients with coronary artery disease, or
- Patients with symptomatic carotid artery disease, or
- Patients with peripheral vascular disease, or
- Patients with abdominal aneurysm, or
- Patients with diabetes mellitus, or
- Patients at a more than 20% 10-year risk of coronary heart disease, or
- LDL-C < 160mg/dL at screening
- Fasting triglyceride (TG) level ≥ 150mg/dL and < 500mg/dL at screening
- HDL-C level <40mg/dL (Male Patient), <50mg/dL(Female Patient)
- Voluntary written informed consent to study participation
Secondary visit (Visit 2 (D0))
- LDL-C < 100mg/dL after the 4-week atorvastatin run-in period
- Fasting TG level ≥ 150mg/dL and < 500mg/dL after the 4-week atorvastatin run-in period
- HDL-C level <40mg/dL (Male Patient), <50mg/dL(Female Patient)
Exclusion Criteria:
- Acute arterial disease (history of unstable angina pectoris, myocardial infarction, acute coronary syndrome, transient ischemic attack, cerebrovascular disease, coronary bypass, or coronary artery disease within 3 months prior to study participation)
- Revascularzation procedure or aortic aneurysm operation within 6 months prior to study participation
- Myopathy, history of rhabdomyolysis or myopathy due to statins or fibrates, or elevated CK level ≥ 5 x upper limit of normal (ULN) during the previous statin treatment
- Acute or chronic pancreatitis due to hypertriglyceridemia
- Cardiovascular, hepatic, neurological, endocrine, or other serious systemic disease that may affect the study conduct or interpretations of the study results
- Known positive serum tests to human immunodeficiency virus (HIV) Antibody I or II
- Diagnosis of cancer within the past 2 years (except successfully treated basal cell carcinoma and squamous cell carcinoma)
- Patients treated with prohibited concomitant medications during the study period or those for whom treatment with prohibited concomitant medications is considered inevitable (systemic or inhalant corticosteroids may be allowed during the study provided that the treatment is maintained at the same dose.)
- Administration of or will be administered with periodic sex hormone therapies or oral contraceptives within 2 months prior to the screening visit or during the study participation
- Moderate to severe renal impairment (GFR<60ml/min) at screening
- Severe hepatic impairment with AST/ALT level > 3 x ULN at screening (biliary cirrhosis, active liver disease, or continued increases in transaminases by unknown causes (> 3 x ULN), etc.)
- Uncontrolled hypothyroidism
- Uncontrolled diabetes mellitus (HbA1c>8.5%)
- Hyperlipidemia Class I, IIa, IV, or V
- Requiring insulin treatment for diabetes mellitus
- Allergies or hypersensitivity reactions to the study drug
- Patients known to have, or suspected of having a history of drug or alcohol abuse within the past 2 years
- Confirmed pregnant or lactating women at screening
- Women of childbearing potential at screening and planning to become pregnant during the study. Women at the childbearing age who did not undergo surgical sterilization may participate in the study only if the pregnancy test is determined negative and should maintain effective contraceptive methods throughout the study period. Periodic abstinence (e.g., calendar method, ovulation method, symptothermal method, post-ovulation method) and self control are not considered to be acceptable contraceptive methods, and use of hormonal contraceptives is not allowed.
- Having participated in another clinical trial within 1 month prior to screening
- History of photoallergic or phototoxic reactions during treatment with fibrates or ketoprofen
- Biliary disease
- Interstitial pulmonary disease
- Other patients considered by the principal investigator or sub-investigator inappropriate for study participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pravastatin 40mg/Fenofibrate160mg
Pravastatin (40mg/day) Fenofibrate (160mg/day)
|
Pravafenix(Pravastatin40mg/Fenofibrate160mg)
Other Names:
Lipitor 10mg(Atorvastatin Sodium)
Other Names:
|
Active Comparator: Atorvastatin Sodium
Atorvastatin Sodium (10mg/day)
|
Pravafenix(Pravastatin40mg/Fenofibrate160mg)
Other Names:
Lipitor 10mg(Atorvastatin Sodium)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change (%) from baseline in Non-HDL-C
Time Frame: at Week 8
|
Percent change (%) from baseline at Week 8 in Non-HDL-C
|
at Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent change (%) from baseline in Non-HDL-C
Time Frame: Week 4
|
Percent change (%) from baseline at Week 4 in Non-HDL-C
|
Week 4
|
◦Percent change (%) from baseline at Week 4 and Week 8 in TG
Time Frame: Week 4 and Week 8
|
Percent change (%) from baseline at Week 4 and Week 8 in TG
|
Week 4 and Week 8
|
Percent change (%) from baseline at Week 4 and Week 8 in TC
Time Frame: Week 4 and Week 8
|
Percent change (%) from baseline at Week 4 and Week 8 in TC
|
Week 4 and Week 8
|
Percent change (%) from baseline at Week 4 and Week 8 in LDL-C
Time Frame: Week 4 and Week 8
|
Percent change (%) from baseline at Week 4 and Week 8 in LDL-C
|
Week 4 and Week 8
|
Percent change (%) from baseline at Week 4 and Week 8 in HDL-C
Time Frame: Week 4 and Week 8
|
Percent change (%) from baseline at Week 4 and Week 8 in HDL-C
|
Week 4 and Week 8
|
Percent change (%) from baseline at Week 4 and Week 8 in Apo A-I
Time Frame: Week 4 and Week 8
|
Percent change (%) from baseline at Week 4 and Week 8 in Apo A-I
|
Week 4 and Week 8
|
Percent change (%) from baseline at Week 4 and Week 8 in Apo B
Time Frame: Week 4 and Week
|
Percent change (%) from baseline at Week 4 and Week 8 in Apo B
|
Week 4 and Week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Hyo-Soo Kim, M.D., Seoul National University Hospital, Department of Internal Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2014
Primary Completion (Actual)
January 1, 2018
Study Completion (Actual)
January 1, 2018
Study Registration Dates
First Submitted
May 27, 2014
First Submitted That Met QC Criteria
June 15, 2014
First Posted (Estimate)
June 18, 2014
Study Record Updates
Last Update Posted (Actual)
September 28, 2018
Last Update Submitted That Met QC Criteria
September 27, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YYP-Pravafenix-C31301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Combined Dyslipidemia
-
Kowa Research EuropeCompletedHypercholesterolemia or Combined DyslipidemiaDenmark, Israel, Netherlands, Germany, United Kingdom
-
AbbottCompletedDyslipidemias | Coronary Heart Disease | Mixed Dyslipidemia | Combined (Atherogenic) DyslipidemiaUnited States
-
Haukeland University HospitalUniversity of BergenCompleted
-
In His ImageKos PharmaceuticalsCompletedDyslipidemia | Hyperlipidemia | Mixed HyperlipidemiaUnited States
-
University of IoanninaUnknown
-
Nanfang Hospital of Southern Medical UniversityThe Affiliated Hospital of Qingdao University; Sun Yat-Sen Memorial Hospital... and other collaboratorsRecruitingVenetoclax Combined With Azacitidine Plus Homoharringtonine | Venetoclax Combined With AzacitidineChina
-
Johns Hopkins UniversityRecruitingADHD - Combined TypeUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedContraceptives, Oral, Combined
-
Merck Sharp & Dohme LLCCompletedVaccines, Combined | Hexavalent VaccineGermany, Italy, Spain
-
Guangzhou General Hospital of Guangzhou Military...UnknownCombined Spinal-epidural AnesthesiaChina